Epitomee Medical News
22 articles
growth-positive
Epitomee's Drug-Free Capsule Helps Patients Shed Pounds: RESET Study Results presented at ObesityWeek® 2024
Epitomee Medical Ltd. presented significant results from its RESET study on a novel oral hydrogel capsule for weight loss at ObesityWeek® 2024. The study demonstrated the capsules efficacy and safety, showing significant weight loss among participants compared to a placebo group. The capsule, which expands in the stomach to enhance satiety and reduce appetite, met its co-primary endpoints, with 55.5% of participants achieving at least 5% body weight reduction at 24 weeks. The study also highlighted improvements in insulin levels and quality of life scores. The capsule offers a safe, drug-free alternative for weight management, particularly for individuals with a BMI starting at 25, where many anti-obesity medications are not approved.
growth-positive
/PRNewswire/ -- Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics...
Epitomee Medical Ltd. is set to present its innovative Oral Delivery of Biologics Platform at the 14th Annual PODD Conference in Boston on October 29, 2024. The presentation, led by Dr. Gil Cohen, VP R&D, will showcase a breakthrough device that enables the oral delivery of large molecules, such as proteins and peptides, significantly enhancing bioavailability. This needle-free platform offers a non-invasive alternative to traditional injections, transporting drugs effectively across the gastrointestinal wall. The PODD Conference is a key event for fostering collaboration among pharma, biotech, and drug delivery sectors, aiming to improve therapies and patient experiences. Epitomee Medical, co-founded by Shimon Eckhouse and led by CEO Dan Hashimshony, focuses on advancing innovative therapies in weight management and biologic drug delivery.
growth-positive
Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference
Epitomee Medical Ltd. announced that it will present its innovative Oral Delivery of Biologics Platform at the 14th Annual PODD Conference in Boston on October 29, 2024. The presentation, led by Dr. Gil Cohen, VP R&D, will showcase the companys breakthrough technology that enables the oral delivery of large molecules, such as proteins and peptides, offering a non-invasive alternative to traditional injections. The platform enhances bioavailability and precisely transports drugs to the small intestine, improving the patient experience. The PODD Conference is a significant event that brings together over 800 delegates from various sectors, fostering collaboration and showcasing innovative drug delivery technologies.
growth-positive
Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Epitomee Medical Ltd. announced that the FDA has cleared its Epitomee® Capsule, an innovative, drug-free ingestible device designed to support weight management in adults with a BMI of 25-40 kg/m². The capsule works by creating a sensation of fullness in the stomach, aiding weight loss. The FDA clearance follows the successful RESET study, which demonstrated significant weight loss and a favorable safety profile. This milestone opens new opportunities for Epitomee in the U.S. market, and the company is seeking strategic partnerships to maximize its commercial potential.
CustomersPartners
growth-positive
/PRNewswire/ -- Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially cleared the Epitomee®...
Epitomee Medical Ltd. announced that the FDA has cleared its Epitomee® Capsule, an innovative, drug-free ingestible device designed to support weight management in adults with a BMI of 25-40 kg/m². The capsule promotes a feeling of fullness, aiding weight loss when used alongside diet and exercise. The FDA clearance follows the successful RESET study, which demonstrated significant weight loss and a favorable safety profile. The company plans to bring this product to the U.S. market and seek strategic partnerships to maximize its commercial potential.
CustomersPartners
growth-positive
Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Epitomee Medical Ltd. announced that the FDA has cleared its Epitomee® Capsule, an innovative, drug-free ingestible device designed for weight management in adults with a BMI of 25-40 kg/m². This capsule promotes a feeling of fullness, aiding in weight loss alongside diet and exercise. The FDA clearance follows the successful RESET study, which demonstrated significant weight loss and a favorable safety profile. The company aims to bring this product to the U.S. market and is seeking strategic partnerships to maximize its commercial potential. The capsule offers a new, effective option for millions of individuals seeking weight management solutions.
CustomersPartners
growth-positive
Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance
Epitomee, a health solutions company, has submitted its Weight Loss Capsule for FDA clearance in the USA. The capsule, which is orally administered and drug-free, has already received approval in the European Union. The company aims to introduce this innovation to healthcare professionals and consumers in the near future and expand its market reach through additional global commercial partnerships. This follows the successful completion of the RESET pivotal clinical trial that investigated the safety and efficacy of the Epitomee capsule.
CustomersPartnersExpand
growth-positive
Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
Epitomee, a health solutions company, announced the successful completion of its RESET pivotal clinical trial for its weight loss capsule. The trial, conducted across nine centers in the U.S., demonstrated the capsules safety and efficacy, with 56% of participants achieving at least 5% weight loss. The study met its primary endpoints and showed no serious adverse events. The results will support a planned FDA regulatory submission, aiming for U.S. market entry. Epitomee is also seeking international commercial partnerships to expand its market presence. The company is publicly traded on TASE under the ticker EPIT.
CustomersPartnersPublic Trading
growth-positive
Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
Epitomee, a health solutions company, has announced the successful completion of the RESET pivotal clinical trial for its weight loss capsule. The trial was conducted in nine centers across the U.S. and included 279 participants. The primary objective was to collect data to support a planned FDA regulatory submission, which would allow the marketing and distribution of the Epitomee capsule in the U.S. The trial demonstrated that the majority of patients using Epitomee achieved 5% or greater weight loss from baseline and showed a favorable safety profile. Epitomee is now seeking further international commercial partnerships to build market presence.
CustomersPartners
growth-negative
Weight loss pill maker Epitomee's stock sinks 70% after Nestlé cancels agreement | CTech
Swiss conglomerate Nestlé has terminated its license agreement with Israeli company Epitomee Medical, which develops a weight loss capsule. The decision was made after clinical trial results did not meet the minimum conditions outlined in the license agreement. The termination of the agreement led to a drop of over 70% in Epitomee’s shares, leaving it with a market cap of around $35 million. Despite Nestlé’s decision, Epitomee is exploring alternative avenues for the commercialization of its product.
PartnersCustomers
growth-positive
תוצאות הניסוי הקליני בגלולת ההרזייה הקפיצו את מניית אפיטומי
Epitomee Medicals stock has surged by 30% following positive results from a clinical trial of its weight loss pill. The results advance the companys position to apply for approval from the US Food and Drug Administration (FDA). In the first half of 2023, Epitomee reported a loss of $5 million, along with negative cash flows from regular operations of a similar amount. By the end of the period, the company had cash and deposits worth $40 million. In December 2021, the company was listed on the Tel Aviv Stock Exchange, raising NIS 185 million at a pre-money valuation of NIS 632 million.
CustomersPartners
growth-negative
Epitomee slumps as Nestle nixes marketing weight loss pill
Epitomee Medical, an Israeli ingestible medical devices company, has announced that its planned marketing partner, Nestlé, has found that the clinical trial results of Epitomees weight loss pill did not meet the targets set out in their agreement. This has led to a 71% drop in Epitomees share price, wiping NIS 310 million off the companys market cap. Epitomee had a valuation of NIS 800 million at its IPO in December 2021, and now it is worth only NIS 126 million.
Partners
growth-negative
לגלולת ההרזיה של אקהויז צפוי קרב קשה מול מלכת השוק הדנית | כלכליסט
Epitomee Medical, an Israeli company, has released the main results of its clinical trial for a weight loss pill it has developed. The pill has shown significant effectiveness, likely enough for FDA approval. However, the results may not satisfy its marketing partner, Nestle, as they are lower than the effectiveness of leading competitor, Wegovy. Epitomee Medical was listed on the stock exchange in December 2021, raising NIS 162 million at a company value of NIS 738 million. The main shareholder is entrepreneur Shimon Eckhouse.
PartnersInvestment
growth-positive
Weight loss pill success sparks stock surge at Epitomee Medical | CTech
Israeli company Epitomee Medical has reported success in a pivotal study of its weight loss capsule, causing its stock to soar on the Tel Aviv Stock Exchange. The companys stock surged by over 70% at one stage, reaching an all-time high and achieving a market cap of over $100 million. Epitomee plans to seek FDA approval for the sale of its medical device via the 510(k) pathway. The company partnered with Nestlé Health Science in the study, and Nestlé has exclusive rights to commercialize the capsule globally. Epitomee completed its IPO in December 2021, raising $51 million at a pre-money valuation of $200 million.
InvestmentPartnersPublic Trading
growth-positive
Epitomee and Nestlé Health Science Announced Completion of Patient Enrollment in Epitomee's Weight Loss Capsule Pivotal Study (United States)
Epitomee, a biomedical company, and Nestlé Health Science have announced the completion of patient enrollment for a pivotal study of Epitomees weight loss capsule. The study, conducted at leading medical centers across the U.S., aims to demonstrate the safety and effectiveness of the capsule over a 24-week treatment period. The results are expected in the second half of 2023. Nestlé Health Science has exclusive rights to commercialize the capsule globally. The capsule is designed to imitate solid food and create a sensation of satiety.
PartnersCustomers
growth-positive
Shimon Eckhouse brings Epitomee Medical to TASE
Epitomee, a company founded by Dr. Shimon Eckhouse, has successfully floated on the Tel Aviv Stock Exchange. The company has developed an ingestible pill for treating obesity and delivering drugs to the stomach. Epitomee raised NIS 162 million at a valuation of NIS 632 million in its recent offering, with Nestlé converting a $7 million loan to equity. The pill expands in the stomach, creating a sensation of fullness. Epitomee has a marketing agreement with Nestlé Health Science, entitling it to receive $115 million in advance and milestone payments. The company plans to start commercial production and sales in early 2023. Epitomees main shareholders include Dr. Shimon Eckhouse, Chinese fund Star Concept, and companies owned by Idan Ofer and Udi Angel.
InvestmentPartners
growth-positive
אקהויז מבסוט מת"א: גלולת ההרזיה של אפיטומי בדרך לבורסה
Epitomee Medical, a medical device company, is planning an initial public offering (IPO) on the Tel Aviv Stock Exchange. The company, which develops an inflatable pill for weight loss, aims to raise around $50 million at a company valuation of at least $200 million. Epitomee has signed an exclusive marketing agreement for its leading product with Nestles medical food division. The company also plans to establish a factory in Israel that will employ about 40 people and be able to produce millions of pills each month.
Public TradingInvestmentExpand
growth-positive
Epitomee Medical Ltd. and Nestlé Health Science Announced Partnership for Development and Commercialization of the Epitomee Weight Loss Capsule
Epitomee Medical has entered into a strategic partnership with Nestlé Health Science for the commercialization of Epitomees weight loss product. Nestlé Health Science has been granted exclusive and global commercial rights to use the product and will utilize its marketing and sales channels to launch it in the global market. The partnership aims to address metabolic disorders and provide a safe and effective solution for people suffering from overweight and its comorbidities. Epitomees first product is a drug-free, self-administered shape-shifting Capsule. The partnership is seen as a recognition of Epitomees good science and vision, and it will enable the worldwide scale-up of the product.
Partners
growth-positive
Epitomee Closed $8M Equity Financing Round - FinSMEs
Epitomee Medical, a bio-medical company based in Israel, has closed an $8 million equity financing round. The funding will be used to advance the companys clinical program and bring its solutions closer to market. Epitomee Medical is developing treatments for the overweight and obese population, including glycemic control, weight reduction, and hypertension. Their flagship product, the Epitomee Capsule, is an orally taken capsule that helps the body have an early sensation of fullness and prolonged gastric emptying, resulting in weight loss. The initial clinical study showed positive results, and the company is now conducting a Phase 2B study. The equity financing round was led by XT Hi-Tech, with participation from GCB and Dr. Shimon Eckhouse.
Investment
growth-positive
The Epitomee Capsule Self-administered Treatment Paradigm for Weight Loss and Body Circumference Reduction Presented at the IsraeLIVE Endoscopy International 2018 Conference
Epitomee Medical presented a novel treatment model for overweight and obesity using the Epitomee capsule device. The treatment involves taking two capsules a day, which contain biodegradable devices that act on the stomach. The treatment has shown a meaningful reduction in weight, improvement in glycemic control, and reduction in waist circumference. The CEO of Epitomee, Hashimshony, stated that their solution is unique and can be scaled up to treat billions of people. Epitomee Medical is a privately held company based in Caesarea, Israel.
Customers
growth-positive
Epitomee Capsule Concept Presented at the Mixii Biomed 2018 Conference
Epitomee Medical presented their concept for weight loss and glycemic control at a conference. The companys self-administered shapeshifting capsule aims to assist in weight loss and better glycemic control. Preliminary clinical results are promising, and the concept could represent a new direction in treating overweight and obesity. Epitomee Medical was founded with the goal of developing ingestible devices to treat chronic diseases in a self-managed, safe, and effective way. The company is privately held and based in Caesarea, Israel.
Customers
growth-positive
Fat transfer co Tulip reports positive trial results
Tulip Medical, an Israeli biomed company, has completed its first clinical trial for a weight-loss pill that expands in the stomach and creates a sense of satiety. The trial showed a 4% reduction in weight among the 16 patients. The company is now moving on to an advanced clinical trial with an inclusive weight-loss program. Tulip Medical has raised $9 million in investment from Canadian investors, the Health 7 fund, and Agate Investment. The expanding pill is digested within a few hours and does not have side effects. The product may receive approval in the EU by the end of the year.
InvestmentExpand
